The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations

Taniguchi, Yoshihito; Matsumoto, Yōko; Furukawa, Ryutaro; Ōhara, S.; Usui, Kazuhiro

doi:10.1007/s10147-017-1233-8

Cited by 10 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from these clinical trials demonstrated that as a maintenance treatment option, the therapeutic effects of erlotinib were similar to those of first- or second-line chemotherapy. Furthermore, the role of afatinib in the treatment of LSCC has been evaluated in several clinical trials 39. Shun Lu and his colleagues conducted a post hoc analysis of the data of patients in the LUX-Lung 8 trial conducted in mainland China 23.…”

Section: Discussionmentioning

confidence: 99%

“…Compared with erlotinib, afatinib reduced the risk of disease progression or death in the Chinese subgroup by 30% (HR, = 0.70; 95% CI, 0.38–1.27), thereby indicating that afatinib may be considered as a feasible treatment option for Chinese patients with advanced LSCC following the progression of the disease after platinum-based chemotherapy. Yuri Taniguchi and his colleagues showed that the administration of afatinib to LSCC patients who were selected using the EGFR mutation test based on the underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib 39…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations

Gao¹,

Zhu²,

Chen³

et al. 2019

CMAR

View full text Add to dashboard Cite

PurposeTo analyze the distribution of epidermal growth factor receptor (EGFR) mutations; characterize the clinical and imageological features of lung squamous cell carcinoma (LSCC) in a large population of patients; and assess correlations between clinical and imageological characteristics and clinical outcomes of LSCC patients harboring EGFR mutations.Patients and methodsThree pathologists retrospectively evaluated the morphological and immunohistochemical data of 2,322 patients with LSCC resected between February 2013 and December 2017. Data on the distribution of EGFR mutations and the clinical and imageological characteristics of the patients were retrospectively collected. Correlations between the EGFR mutation status and clinical outcomes were evaluated using univariate and multivariate analyses.ResultsEGFR mutations were found in 3.4% of patients with LSCC and predominantly in female and non-smoking patients. Tumor lesions in patients with EGFR-positive mutations were more irregularly shaped than those in patients with EGFR-negative mutations (P = 0.045). In non-smoking patients with LSCC, the proportion of marked spiculation was significantly higher in the EGFR-positive group than in the EGFR-negative group (P = 0.043). No significant difference in recurrence-free survival was noted between LSCC patients harboring EGFR-positive and those harboring EGFR-negative mutations. No difference in metastases was observed between the EGFR-positive and EGFR-negative cohorts.ConclusionFemale gender, non-smoking habit, irregularly shaped tumor, and marked spiculation might predict the presence of EGFR mutations in LSCC. The administration of tyrosine kinase inhibitors to patients with LSCC after screening for EGFR mutations based on their clinical and imageological features would likely result in a population with a greater sensitivity to afatinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations

Gao¹,

Zhu²,

Chen³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…In addition, a study has shown afatinib to be more effective than erlotinib as a second-line treatment for patients with advanced SCC (15). Furthermore, a study retrospectively reviewing patients with EGFR -mutated squamous cell carcinoma treated with EGFR -TKIs as first-line therapies revealed that afatinib was effective in two of two cases, while gefitinib was not effective in two of two cases (16). From these and the present case findings, we suggest that afatinib can be considered as a treatment option for EGFR -mutated tumors undergoing SCC transformation, particularly those without T790M mutation.…”

Section: Discussionmentioning

confidence: 99%

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib

et al. 2018

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

show abstract

“…So most patients with lung SCC have no chance to get benefit from EGFR tyrosine-kinase inhibitors (TKIs). However, it was found in the subgroup analysis of several studies that among all lung SCC patients, the EGFR mutation rate in female patients seemed to be higher, about 14.4% to 33.3% (6,10,11,14). But the sample size of female SCC in these studies were very small, and at present there was no specific study on EGFR mutation status in female lung SCC.…”

Section: Introductionmentioning

confidence: 92%

“…Previous respective studies showed that lung SCC patients with sensitive EGFR mutations could obtain clinical benefits from EGFR-TKIs (9,13,24). While in a study of Turkish female lung SCC patients with EGFR positive mutation, the response to gefitinib was not good (14). Therefore, the efficacy of EGFR-TKIs for female lung SCC patients with sensitive EGFR mutations remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

et al. 2021

View full text Add to dashboard Cite

BackgroundThe frequency of epidermal growth factor receptor (EGFR) mutations and the efficacy of tyrosine kinase inhibitor (TKI) in Chinese female patients with lung squamous cell carcinoma (SCC) are unknown. This study was designed to investigate the incidence of EGFR mutations and the role of targeted therapy in advanced Chinese female lung SCC patients.MethodsAdvanced female patients diagnosed with lung SCC at the Shanghai Chest Hospital between January 2013 and December 2018 were retrospectively analyzed.ResultsA total of 4223 advanced lung SCC patients were screened, and there were 154 female lung SCC patients who had underwent EGFR mutation detection. Positive EGFR mutations were found in 29.9% (46/154) of female lung SCC patients, including twenty-three 19del mutation (14.9%), twenty-one 21L858R mutation (13.6%) and other mutations (1.4%, 21861Q and 20ins). For 45 EGFR positive mutation female SCC patients, the median progression-free survival (PFS) of patients who received EGFR-TKI therapy (n=38) was 8.0 months (95% CI, 5.4-10.7 months), which was significantly longer than patients who were treated with chemotherapy (8.0 vs. 3.2 months, p=0.024), and the median overall survival (OS) was also longer (24.9 months vs. 13.9 months, p=0.020). The objective response rate (ORR) was 44.7% (17/38), and the disease control rate (DCR) was 81.6% (31/38). For 105 female SCC patients with EGFR negative mutation, the median OS was 18.6 months (95% CI, 14.2-22.9 months) and it was no different from that of EGFR positive mutation patients (18.6 vs. 22.8 months, p=0.377).ConclusionFor advanced Chinese female lung SCC patients with EGFR positive mutations, targeted therapy could confer longer PFS and OS than chemotherapy, but the survival was similar with patients who were negative EGFR mutations.

show abstract

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations

Abstract: The administration of afatinib to Sq patients after selecting patients using the EGFR mutation test based on their underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib.

Cited by 10 publications

References 22 publications

<p>Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With <em>EGFR</em> Mutations</p>

<p>Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With <em>EGFR</em> Mutations</p>

An <i>EGFR</i>-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

Contact Info

Product

Resources

About